MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Comparision of objective Parkinson’s disease monitoring systems and the interpretations of results

    G. Kilincalp, F. Grahn, H. Sabir, D. von Below, A. Jeppsson, A. Sjöström, F. Bergquist (Gothenburg, Sweden)

    Objective: To examine the agreeement between two objective Parkinson’s disease (PD) monitoring systems (PKG and STAT-ON) and clinical information from a resident physician’s interview or…
  • 2023 International Congress

    What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)

    R. Hauser, S. Allard, G. Banisadr, S. Fisher (Tampa, USA)

    Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…
  • 2023 International Congress

    Movement disorders in the setting of dengue infection in a rural medical teaching hospital in Gujarat, India

    D. Desai, S. Desai (Anand, India)

    Objective: To determine the frequency and types of movement disorders in patients with dengue. Background: Dengue fever is a common viral infection presenting with fever,…
  • 2023 International Congress

    COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometery

    T. Nesser, T. Dembek, C. Hennen, V. Stopic, M. Barbe (Cologne, Germany)

    Objective: To investigate the continuous and objective assessment of motor symptom severity in Parkinson’s Disease (PD) in everyday life. Background: Treatment adjustments in PD patients…
  • 2023 International Congress

    Neuropalliative communication curriculum: A review of the literature and needs assessment

    K. Block, A. Hiller, N. Leavell, S. Sorge (Portland, USA)

    Objective: We aim to improve neuropalliative education in neurology trainees by creating a reproducible didactic curriculum targeting specific communication techniques using case-based sensitive scenarios commonly…
  • 2023 International Congress

    Inferring Rigidity Scores in MDS-UPDRS Motor Assessment from Other Items

    F. Duque Quiceno, Y. Dushin, G. Sarapata, S. Komarov, A. Matveev, J. O'Keeffe (London, United Kingdom)

    Objective: This study aimed to explore the possibility of inferring rigidity scores in MDS-UPDRS assessments from other items to enhance the accuracy of clinical evaluations…
  • 2023 International Congress

    Examining the Correlation Between Multi-Spectral Diffusion Weighted Imaging Quantitative Maps and Unified Parkinson’s Disease Rating Scale Scores

    I. Shelley, I. Ailes, M. Syed, K. Shivok, J. Miao, L. Krisa, F. Mohamed, R. Sergott, T. Liang, A. Sharan, M. Kogan, C. Wu, M. Alizadeh (Philadelphia, USA)

    Objective: We aimed to correlate Unified Parkinson’s Disease Rating Scale (UPDRS) scores with quantitative maps to determine the ability to generate non-invasive biomarkers for Parkinson’s…
  • 2023 International Congress

    Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson’s disease

    A. Hach, Z. Landoulsi, B. Meier, P. Seibler, C. Klein, P. May, A. Rakovic (Luebeck, Germany)

    Objective: To identify novel genes and pathways acting as modifiers of pathogenic Parkin variant (PV) penetrance in affected compared to unaffected carriers of heterozygous Parkin PVs…
  • 2023 International Congress

    Obesity is a protective factor for the development of Parkinson’s disease in participants of the Framingham Heart Study Cohort

    S. O'Shea, Y. Liu, C. Liu, S. Frank, R. Au (New York, USA)

    Objective: To determine the role of obesity in the development of Parkinson's disease in a retrospective matched cohort study. Background: Parkinson’s disease (PD) is a…
  • 2023 International Congress

    Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial

    C. Laurencin, A. Marques, D. Dilly Duchez, C. Giordana, S. Meoni, M. Anheim, P. Boulinguez, B. Ballanger, S. Thobois (Lyon, France)

    Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 229
  • 230
  • 231
  • 232
  • 233
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley